Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 50.36
NLNK's Cash to Debt is ranked higher than
73% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. NLNK: 50.36 )
NLNK' s 10-Year Cash to Debt Range
Min: 1.05   Max: 50.36
Current: 50.36

1.05
50.36
Equity to Asset 0.83
NLNK's Equity to Asset is ranked higher than
86% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NLNK: 0.83 )
NLNK' s 10-Year Equity to Asset Range
Min: -3.25   Max: 0.83
Current: 0.83

-3.25
0.83
F-Score: 4
Z-Score: 25.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2849.13
NLNK's Operating margin (%) is ranked higher than
51% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. NLNK: -2849.13 )
NLNK' s 10-Year Operating margin (%) Range
Min: -2849.13   Max: -801.39
Current: -2849.13

-2849.13
-801.39
Net-margin (%) -2852.70
NLNK's Net-margin (%) is ranked higher than
51% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. NLNK: -2852.70 )
NLNK' s 10-Year Net-margin (%) Range
Min: -2852.7   Max: -779.85
Current: -2852.7

-2852.7
-779.85
ROE (%) -53.46
NLNK's ROE (%) is ranked higher than
61% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. NLNK: -53.46 )
NLNK' s 10-Year ROE (%) Range
Min: -130.09   Max: -49.19
Current: -53.46

-130.09
-49.19
ROA (%) -44.19
NLNK's ROA (%) is ranked higher than
62% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. NLNK: -44.19 )
NLNK' s 10-Year ROA (%) Range
Min: -86.63   Max: -37.39
Current: -44.19

-86.63
-37.39
ROC (Joel Greenblatt) (%) -472.76
NLNK's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. NLNK: -472.76 )
NLNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -586.24   Max: -306.49
Current: -472.76

-586.24
-306.49
Revenue Growth (%) -59.90
NLNK's Revenue Growth (%) is ranked higher than
55% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. NLNK: -59.90 )
NLNK' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -59.9
Current: -59.9

EBITDA Growth (%) -36.90
NLNK's EBITDA Growth (%) is ranked higher than
56% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. NLNK: -36.90 )
NLNK' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -36.9
Current: -36.9

EPS Growth (%) -36.70
NLNK's EPS Growth (%) is ranked higher than
57% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. NLNK: -36.70 )
NLNK' s 10-Year EPS Growth (%) Range
Min: 0   Max: -36.7
Current: -36.7

» NLNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

NLNK Guru Trades in Q1 2013

Jim Simons 13,300 sh (New)
Jean-Marie Eveillard 328,939 sh (New)
» More
Q2 2013

NLNK Guru Trades in Q2 2013

Jean-Marie Eveillard 641,554 sh (+95.04%)
Jim Simons Sold Out
» More
Q3 2013

NLNK Guru Trades in Q3 2013

Jean-Marie Eveillard 778,354 sh (+21.32%)
Jean-Marie Eveillard 1,078 sh (unchged)
» More
Q4 2013

NLNK Guru Trades in Q4 2013

Jim Simons 28,200 sh (New)
Jean-Marie Eveillard 905,154 sh (+16.29%)
Jean-Marie Eveillard 5,965 sh (unchged)
Jean-Marie Eveillard 2,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NLNK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-09-30 Add 21.32%0.01%$15.78 - $20.08 $ 20.8517%778354
Jean-Marie Eveillard 2013-06-30 Add 95.04%0.02%$11.27 - $22.56 $ 20.8532%641554
Jean-Marie Eveillard 2013-03-31 New Buy0.01%$11.4 - $12.7 $ 20.8573%328939
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.48
NLNK's P/B is ranked lower than
58% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. NLNK: 9.48 )
NLNK' s 10-Year P/B Range
Min: 3.6   Max: 22.83
Current: 9.48

3.6
22.83
P/S 521.25
NLNK's P/S is ranked lower than
89% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. NLNK: 521.25 )
NLNK' s 10-Year P/S Range
Min: 14   Max: 1255.5
Current: 521.25

14
1255.5
EV-to-EBIT -16.72
NLNK's EV-to-EBIT is ranked lower than
82% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. NLNK: -16.72 )
NLNK' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -16.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.21
NLNK's Price/Net Cash is ranked lower than
53% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. NLNK: 11.21 )
NLNK' s 10-Year Price/Net Cash Range
Min: 4.76   Max: 25.51
Current: 11.21

4.76
25.51
Price/Net Current Asset Value 10.97
NLNK's Price/Net Current Asset Value is ranked lower than
51% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. NLNK: 10.97 )
NLNK' s 10-Year Price/Net Current Asset Value Range
Min: 4.72   Max: 24.51
Current: 10.97

4.72
24.51
Price/Tangible Book 9.47
NLNK's Price/Tangible Book is ranked lower than
61% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. NLNK: 9.47 )
NLNK' s 10-Year Price/Tangible Book Range
Min: 3.93   Max: 14.71
Current: 9.47

3.93
14.71
Price/Median PS Value 3.12
NLNK's Price/Median PS Value is ranked lower than
64% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NLNK: 3.12 )
NLNK' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 3.29
Current: 3.12

0.09
3.29

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4NX.Germany
NewLink Genetics Corp., was incorporated in Delaware on June 4, 1999. The company is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small‑molecule immunotherapy product candidates intended to treat a range of oncology indications. Its lead product candidate, HyperAcute Pancreas cancer immunotherapy, or HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically‑resected pancreatic cancer patients that is being performed under a Special Protocol Assessment, or SPA, with the United States Food and Drug Administration, or FDA. The company initiated this trial based on encouraging interim Phase 2 data that suggests improvement in both disease-free and overall survival. The company has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically‑resected pancreatic cancer. It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy, or HyperAcute Lung, which is being studied in a Phase 1/2 clinical trial at the National Cancer Institute, or NCI, and its HyperAcute Melanoma cancer immunotherapy, or HyperAcute Melanoma, which is being studied in an investigator‑initiated Phase 2 clinical trial. To date, its HyperAcute product candidates have been dosed in more than 200 cancer patients either as a monotherapy or in combination with other therapies and have demonstrated a favorable safety profile. Its HyperAcute product candidates are based on its proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its HyperAcute product candidates use allogeneic (non‑patient specific) cells from previously established cell lines rather than cells derived from the patient. The company thinks its approach enables a simpler, consistent and scalable manufacturing process than therapies based on patient specific tissues or cells. Its strategy is to discover, develop and commercialize immunotherapeutic products for the treatment of cancer where the needs of patients are unmet by current therapies. The company faces competition from other public and private biopharmaceutical companies, public and private universities and research organizations actively engaged in the discovery and research and development of products for cancer. The company is subject to federal, state, local and foreign regulation.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide